Robert Barrow Linkedin Team icon

Chief Executive Officer and Board Director

Mr. Barrow is an accomplished pharmaceutical executive and clinical pharmacologist with over a decade of experience leading drug development programs in a variety of disease areas. Mr. Barrow previously served as Director of Drug Development & Discovery at Usona Institute, where he oversaw preclinical, clinical and regulatory development efforts for all of Usona’s development programs. Prior to joining Usona, Mr. Barrow served as Chief Operating Officer of Olatec Therapeutics where he oversaw the execution of numerous early- and late-stage clinical trials in the fields of analgesics, rheumatology, immunology and cardiovascular disease. In addition, he has been responsible for the design and execution of preclinical research programs for new molecular entity drugs in CNS conditions such as multiple sclerosis, Alzheimer’s Disease and Parkinson’s Disease. Mr. Barrow holds a Masters degree in Pharmacology from The Ohio State University and a Bachelor of Science degree from Wake Forest University, where he graduated summa cum laude.

Robert Barrow

Chief Executive Officer and Board Director

Miri Halperin Wernli, PhD

Executive President and Board Director

Cynthia Hu, JD

Chief Legal Officer & Corporate Secretary

Daniel R Karlin, MD MA

Chief Medical Officer

Dave Guebert

Chief Financial Officer

Robert Malenka, MD PhD

Chairman of the Scientific Advisory Board, Nancy Friend Pritzker Professor in Psychiatry and Behavioral Sciences at Stanford University

Peter Bergethon, MD

Member, Scientific Advisory Board VP, Head of Quantitative & Clinical Technologies, Biogen, Inc.

Robert Dworkin, PhD

Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry at University of Rochester

Maurizio Fava, MD

Member, Scientific Advisory Board Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH)

Maria A Oquendo, MD PhD

Ruth Meltzer Professor and Chairman of Psychiatry at University of Pennsylvania, Psychiatrist-in-Chief at the Hospital of the University of Pennsylvania

Bryan L Roth, MD PhD

Professor of Pharmacology, University of North Carolina School of Medicine; Director of the National Institute of Mental Health Psychoactive Drug Screening Program

Kenneth Alper, MD

Clinical Associate Professor of Psychiatry and Neurology at the New York University School of Medicine

Peter Gasser, MD

Clinical Advisor

Stanley D Glick, MD PhD

Scientific Advisor

Matthew W Johnson, PhD

Clinical Advisor

Kim PC Kuypers, PhD

Scientific Collaborator & Advisor

Matthias Liechti, MD PhD

Scientific Collaborator & Advisor

Sarah McCallum, PhD

Associate Professor of Neuroscience and Experimental Therapeutics (DNET) at Albany Medical College

Natalie Wheeler, PhD

Medical Science Liaison with Dova Pharmaceuticals

John Rotrosen, MD

Professor of Psychiatry with New York University’s Langone’s Department of Psychiatry

Carol Vallone

Chair of the Board of Directors, Chair of Compensation Committee, Member of Audit/Finance Committee

Andreas Krebs

Vice Chair of the Board of Directors, Chair of Nomination and Governance Committee, Member of Audit/Finance Committee

Sarah Y Vinson, MD

Board Director, Member of Compensation, Nomination, and Governance Committees

Brigid Makes

Board Director, Chair of Audit/Finance Committee, Member of Compensation Committee, Member of Nomination and Governance Committee

JR Rahn

Co-Founder

Stephen L Hurst, JD

Co-Founder

Scott Freeman, MD

Co-Founder

Leonard Latchman

Co-Founder

Carrie Liao, CPA

VP, Corporate Controller & Accounting Principal